Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,335,837 papers from all fields of science
Search
Sign In
Create Free Account
Myelosuppressive Therapy
Treatment that inhibits blood cell production.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
The Risk of Severe Bacterial Infection in Non-Immunocompromised Neutropenic Infants and Children from 3 Months to 18 Years of Age: A 5 Years Case-Control Study with Literature Review
B. A. Merhi
,
Mazhar Ghieh
,
+6 authors
Imad Chokr
2017
Corpus ID: 212571010
Only a few reports have looked into the risk of invasive bacterial infection in children with neutropenia that is not malignancy…
Expand
2009
2009
Platelet production rate in polycythemia vera after myelosuppressive therapy.
J. Kutti
Acta Medica Scandinavica
2009
Corpus ID: 38932291
In nine cases of polycythemia vera (PV) treated with myelosuppressive agents and considered to be in remission the platelet…
Expand
2008
2008
Risk of hospitalization with pegfilgrastim versus filgrastim prophylaxis: A retrospective cohort study
D. Weycker
,
J. Malin
,
+4 authors
G. Oster
2008
Corpus ID: 57550342
6580 Background: Risk of febrile neutropenia has been reported to be lower with pegfilgrastim (PEG) than filgrastim (FIL) in…
Expand
2002
2002
Phase I S tudy o f C ombination T opotecan a nd C arboplatin in P ediatric S olid T umors
U. Athale
,
C. Stewart
,
+5 authors
R. Heideman
2002
Corpus ID: 78418113
Purpose: We conducted a phase I trial of escalating doses of topotecan (TOPO) in association with a fixed systemic exposure of…
Expand
2001
2001
Intravenöse Immunglobuline in der Infektionsprävention bei Kindern mit hämatologisch-onkologischen Erkrankungen
T. Lehrnbecher
2001
Corpus ID: 58731800
Treatment with intensive myelosuppressive therapy results in decreased levels of immunoglobulins. Whereas pediatric cancer…
Expand
1999
1999
Phase I a nd P harmacokinetic S tudy o f T emozolomide on a D aily-for-5-Days S chedule i n P atients With A dvanced S olid M alignancies
L. Hammond
,
J. Eckardt
,
+9 authors
E. Rowinsky
1999
Corpus ID: 78120226
Purpose: To determine the principal toxicities, characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of…
Expand
1984
1984
Phase I study of mitoxantrone on a daily × 5 schedule
M. Goldsmith
,
T. Ohnuma
,
I. Jaffrey
,
E. Greenspan
,
J. Holland
American Journal of Clinical Oncology
1984
Corpus ID: 22810030
MITOXANTRONE (Nsc-301739) IS A SYNTHETIC AMINO anthraquinone DNA intercalater active in several experimental tumor systems…
Expand
1979
1979
Prospects for accelerating hematopoietic recovery following myelosuppressive therapy by using autologous, cryopreserved hematopoietic stem cells collected solely from the peripheral blood.
Abrams Ra
,
Deisseroth Ab
1979
Corpus ID: 88536034
: Cryopreserved, autologous stem cells collected from human marrow have been used to accelerate hematopoietic recovery following…
Expand